- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02278159
Evaluation of the Integrated Home Dialysis Model
October 27, 2014 updated by: David Johnson, Princess Alexandra Hospital, Brisbane, Australia
The purpose of this study is to evaluate which home dialysis modality pattern (home hemodialysis [HHD], peritoneal dialysis [PD] or a combination of both, e.g.
PD and then HHD) allows for the longest home dialysis survival, as defined by the time dialysed in a home environment.
The investigators hypothesize that patients transferred from one home modality to another will have a longer home dialysis survival compared to patients treated only with PD or HHD.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
11600
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with home dialysis as the first renal replacement therapy [RRT] modality (defined by the dialysis modality at 90 days) in Australia and New Zealand as reported in Australia and New Zealand Dialysis and Transplant Registry [ANZDATA]
Description
Inclusion Criteria:
- Patients with PD/HHD 90 days after RRT initiation between January 1, 2000 and December 31, 2012 reported in ANZDATA
- ≥ 18 years
Exclusion Criteria:
- Less than 90 days of dialysis
- < 18 years
- Patients transferred to Australia/New Zealand after initiation of dialysis in another country
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Peritoneal dialysis only
Patient on PD modality 90 days after renal replacement therapy initiation and not transferred to HHD
|
|
|
Home hemodialysis only
Patient on HHD 90 days after renal replacement therapy initiation and not transferred to PD
|
|
|
PD and HHD
Patient on PD 90 days after RRT initiation and transferred to HHD less than 90 days after PD failure
|
|
|
HHD and PD
Patient on HHD after RRT initiation and transferred to PD less than 90 days after HHD failure
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Home dialysis survival
Time Frame: Survival analysis; specific analysis at 5 years after dialysis initiation
|
Time to first patient death or home dialysis technique failure for each home dialysis modalities, censored for transplantation and loss to follow-up
|
Survival analysis; specific analysis at 5 years after dialysis initiation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient survival, censored for technique failure
Time Frame: Survival analysis, specific analysis at 1,2 5 years after dialysis initiation
|
Patient survival on each specific home dialysis modality, censored for technique failure, transplantation and loss to follow-up
|
Survival analysis, specific analysis at 1,2 5 years after dialysis initiation
|
|
Home technique survival, censored for death
Time Frame: survival analysis, specific analysis at 1,2 5 years after dialysis initiation
|
Home dialysis technique survival for each home dialysis modality, censored for patient death, transplantation and loss to follow-up
|
survival analysis, specific analysis at 1,2 5 years after dialysis initiation
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Home dialysis survival, case-control analysis
Time Frame: survival analysis, specific analysis at 1,2 5 years after dialysis initiation
|
Case-control analysis will be performed in order to address immortal bias in patients classified in the "switching"categories (PD-HHD or HHD-PD).
Since we expect the HHD-PD group to be small, this analysis will be performed only with the 3 other groups (PD-HHD, PD only and HHD only).
Patients treated successively with PD and HHD (cases) will be matched (by age and diabetes status) to patient treated with PD only and HHD only (controls).
|
survival analysis, specific analysis at 1,2 5 years after dialysis initiation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2000
Primary Completion (Actual)
December 1, 2012
Study Completion (Actual)
December 1, 2012
Study Registration Dates
First Submitted
June 19, 2014
First Submitted That Met QC Criteria
October 27, 2014
First Posted (Estimate)
October 29, 2014
Study Record Updates
Last Update Posted (Estimate)
October 29, 2014
Last Update Submitted That Met QC Criteria
October 27, 2014
Last Verified
October 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ANZ41367
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Failure, Chronic
-
Centre Hospitalier Universitaire DijonTerminatedEnd-stage Chronic Kidney FailureFrance
-
Texas A&M UniversityWithdrawnChronic Kidney FailureUnited States
-
Angiodynamics, Inc.TerminatedChronic Kidney Disease | Acute Kidney Injury | Acute Renal Failure | Renal Failure Chronic Contrast InducedUnited States
-
Hopital Jean MinjozUnknownCardiac Surgical Procedures | Preoperative KIDNEY FAILURE, CHRONIC | Postoperative KIDNEY FAILURE, ACUTEFrance
-
Pharmagest InteractiveCompletedChronic Kidney DiseasesFrance
-
Bristol-Myers SquibbCompletedKidney Transplantation | Chronic Kidney FailureUnited States, Argentina, Australia, Germany, Italy, South Africa, Spain, Brazil, Mexico, Belgium, France, Hungary, Switzerland, India, Canada, Austria, Czech Republic, Poland, Israel, Sweden, Turkey
-
Emory UniversityGenentech, Inc.TerminatedKidney Transplantation | Chronic Kidney FailureUnited States
-
Ozge AKBABAAtaturk UniversityCompletedChronic Kidney FailureTurkey
-
Chinese PLA General HospitalCompletedKidney Failure,ChronicChina
-
Fatma Alzahraa Mohamed Ibrahim Hassan HaggagUnknown
Clinical Trials on Peritoneal dialysis
-
Chinese PLA General HospitalCompletedKidney Failure,ChronicChina
-
University of AlbertaWomen and Children's Health Research Institute, CanadaCompletedHypoplastic Left Heart SyndromeCanada
-
Çanakkale Onsekiz Mart UniversityCompletedHemodialysis | Dialysis | Chronic Kidney Disease-Mineral and Bone Disorder | Chronic Kidney FailureTurkey (Türkiye)
-
Universitaire Ziekenhuizen KU LeuvenCompletedChronic Kidney DiseaseBelgium
-
Baxter Healthcare CorporationCompletedEnd Stage Renal DiseaseChina
-
Chinese University of Hong KongCompletedRenal Failure | End-stage Renal DiseaseHong Kong
-
Instituto Mexicano del Seguro SocialUniversidad de GuanajuatoActive, not recruitingHypertension | Diabetic Kidney Disease | Chronic Kidney Disease | Peritoneal Dialysis (PD) | Hypertension With Renal DysfunctionMexico
-
Peking Union Medical College HospitalBeijing Anzhen Hospital; First Hospital of China Medical University; The Luhe... and other collaboratorsTerminated
-
Nanfang Hospital, Southern Medical UniversityGuangdong Provincial Hospital of Traditional Chinese Medicine; Guangzhou First... and other collaboratorsCompleted
-
Chengdu Qingshan Likang Pharmaceutical Co., LtdRecruitingEnd Stage Renal Disease (ESRD)China